Mamaearth Q1 Results: Net profit rises 119% YoY to ₹904.5 million
Honasa Consumer Limited posted a 119% YoY jump in net profit to ₹904.48 million for Q1FY26, driven by 27% revenue growth to ₹7,559.46 million. The company also won an arbitration case against its UAE distributor, securing a claim of ₹255.36 million, and approved the acquisition of a majority stake in Fluence Pharma.

*this image is generated using AI for illustrative purposes only.
Honasa Consumer Limited ( mamaearth ) delivered a strong start to FY26, with consolidated net profit after tax rising 119% year-on-year to ₹904.48 million for the quarter ended June 30, 2026. This compares to ₹413.25 million in Q1FY25. Revenue from operations expanded 27% to ₹7,559.46 million, up from ₹5,952.54 million in the corresponding prior period.
The profit surge was driven by robust top-line growth alongside controlled expense management. While total expenses increased to ₹6,592.70 million from ₹5,635.51 million, the profit before tax more than doubled to ₹1,192.44 million from ₹555.93 million. Other income contributed ₹225.11 million, slightly lower than the ₹238.90 million recorded in Q1FY25.
Financial Performance
| Metric | Q1FY26 | Q1FY25 | Change |
|---|---|---|---|
| Revenue from operations | ₹7,559.46 million | ₹5,952.54 million | +27.0% |
| Profit before tax | ₹1,192.44 million | ₹555.93 million | +114.5% |
| Net profit after tax | ₹904.48 million | ₹413.25 million | +119.0% |
| Earnings per share (basic) | ₹2.77 | ₹1.27 | +118.1% |
Standalone results mirrored the consolidated trend, with net profit reaching ₹843.12 million compared to ₹399.01 million in Q1FY25. Standalone revenue grew 19% to ₹6,963.18 million.
What the Numbers Show
The company’s effective tax rate for the quarter stood at approximately 24.1%, calculated on total tax expenses of ₹287.96 million against a profit before tax of ₹1,192.44 million. This is higher than the implied rate in Q1FY25, where tax expenses were ₹142.68 million on a profit before tax of ₹555.93 million (approx. 25.7%), suggesting a stabilization in tax provisioning despite deferred tax credits in the prior year.
Legal and Strategic Developments
Honasa secured a significant legal victory in its dispute with RSM General Trading LLC, its former overseas distributor. An arbitral tribunal passed a final award in favor of Honasa on May 14, 2026, declaring that RSM breached the arbitration agreement by pursuing proceedings in Dubai courts. The tribunal ordered RSM to pay approximately AED 9.92 million (₹255.36 million) towards various claims filed by Honasa.
The Board of Directors approved the acquisition of a 58% majority stake in Fluence Pharma Private Limited on June 23, 2026, subject to closing adjustments. The remaining 42% stake will be acquired in two tranches over the next five to seven years. Additionally, the company incorporated a wholly owned subsidiary, Honasa Health Private Limited, on July 7, 2026, to handle business-to-consumer nutraceutical operations.
Dividend and Share Capital
The Board recommended a final dividend of ₹3 per equity share for FY26, subject to shareholder approval at the upcoming Annual General Meeting. During the quarter, paid-up equity share capital increased to ₹3,260.24 million from ₹3,253.70 million following the exercise of stock options by employees.
Historical Stock Returns for Mamaearth
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.58% | +4.31% | +1.52% | +60.22% | +78.04% | +42.23% |
How will the acquisition of Fluence Pharma and the launch of Honasa Health impact Honasa's revenue mix and profit margins in the upcoming fiscal years?
Will the legal victory against RSM General Trading LLC accelerate Honasa's re-entry strategy into international markets, and which regions are prioritized next?
Can Honasa sustain its current 27% top-line growth trajectory amidst increasing competition in the D2C personal care sector and potential saturation in domestic markets?


































